Health ❯ Pharmaceuticals

Clinical Trials

Drug Development Drug Safety Weight Loss Drugs Regulatory Compliance Regulatory Affairs Weight Loss Cancer Treatment Osteogenesis Imperfecta Regulatory Approval Obesity Treatments

Alumis Lupus Trial Fails Primary Endpoint: IFNGS‑High Patients Show Benefit

Company will seek regulator guidance on a Phase 3 program focused on the interferon‑high subgroup.

Lilly Sues Six U.S. Sellers Over Black‑Market Sales of Unapproved Retatrutide

Novo Nordisk Starts Late-Stage Trial to Find Lowest Effective Wegovy Pill Dose

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

Kalshi Opens Betting Markets for Phase 3 Drug Trials and FDA Decisions

Fulcrum Halts Pociredir Development After FDA Flags PRC2 Cancer Risk

Law Firms Seek Lead Plaintiffs in Gossamer Bio Securities Suit Before June 1 Deadline

Investors Vie to Lead ImmunityBio Securities Suit

Immunovant Shares Surge on Strong Rheumatoid Arthritis Data for IMVT-1402

Gossamer Bio Investors Face June 1 Deadline in Securities Class Action

Nektar Securities Suit Urges Investors To Seek Lead‑Plaintiff Status Before May 5

Novo Nordisk’s Oral Semaglutide Lowers HbA1c in Teens in Pivotal Trial

Law Firms Urge Nektar Investors to Seek Lead Role in Securities Suit Over REZOLVE-AA Protocol Claims

Insmed Halts Brensocatib in Hidradenitis Suppurativa After Phase 2b Trial Fails

Soleno Investors Urged To Seek Lead Role in Securities Case Before May 5 Deadline

Law Firms Urge Nektar Investors to Join Securities Suit Before May 5

Investor Lawsuits Target Gossamer Bio Over Failed PROSERA Trial

ImmunityBio Faces Growing Securities Suits After FDA Flags Misleading Anktiva Claims

Law Firm Seeks Nektar Investors to Lead Securities Suit Over REZOLVE‑AA Trial Claims

Soleno Hit With Securities Class Action Over Prader‑Willi Drug DCCR